Westwood Holdings Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Westwood Holdings Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,467	Closed	-$252K	–	517
2023 Q2	$252K	Hold	2,467	–	–	﹤0.01%	453
2023 Q1	$224K	Buy	+2,467	New	+$145K	﹤0.01%	472

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Westwood Holdings Group's RETA Position: Q3 2023 in Review

Westwood Holdings Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,467 shares — an estimated $252K sold.

Westwood Holdings Group first reported a position in RETA in Q1 2023 and held it in 2 quarters. The position peaked at $252K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Westwood Holdings Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Westwood Holdings Group sold 2,467 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $252K.
Westwood Holdings Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 2 quarters.
Westwood Holdings Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $252K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Westwood Holdings Group's 13F filing for Q3 2023, filed 14 Nov 2023.